Burlingame, Calif., April 10, 2018 --- Inflammatix announced today that it has been named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests, which read the immune system to tackle the global health problems of antibiotic resistance and sepsis. The annual award honors businesses, policies, projects and concepts that offer [...]
Bioinformatics Approach Forms the Basis of Inflammatix’s HostDx™ Sepsis Test Burlingame, Calif., February 15, 2018 --- Inflammatix announced findings from a new study published today in Nature Communications that suggest that diagnosing and determining who will likely develop sepsis can be improved with a data-driven approach that measures the immune system response to severe infection. [...]
BURLINGAME, Calif., Dec. 19, 2017 /PRNewswire/ -- Inflammatix, a molecular diagnostics company that is developing rapid tests that read the immune system to improve disease diagnosis, today announced that Oliver Liesenfeld, M.D., has been appointed chief medical officer. Dr. Liesenfeld, a veteran of the diagnostics industry, comes to the company from Roche Molecular Diagnostics, where he served as chief [...]
Inflammatix is reimagining diagnostics by developing rapid tests that read the immune system to resolve major clinical and public health challenges. Our initial focus is on acute bacterial and viral infections, and sepsis.
We’re seeking teammates with expertise, curiosity and passion for solving clinical challenges with a focus on patient outcomes. If that sounds like you, check out our Careers Page.
© Copyright, Inflammatix, Inc. All Rights Reserved | Terms & Conditions | Privacy & Cookies Statement
Inflammatix, TriVerity, Myrna, and BacVerity are trademarks of Inflammatix, Inc.